Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Nov 19;272(12):775.
doi: 10.1007/s00415-025-13516-z.

Assessment of IBM-FRS total score and specific functional domains in a large cohort of inclusion body myositis patients

Affiliations
Multicenter Study

Assessment of IBM-FRS total score and specific functional domains in a large cohort of inclusion body myositis patients

Alex Vicino et al. J Neurol. .

Abstract

Inclusion body myositis (IBM) is an acquired myopathy of older adults, associated with progressive weakness and functional limitations. The inclusion body myositis functional rating score (IBM-FRS) is a reliable tool for the assessment of disease severity, but poor data are available on its correlation with clinical features. In this cross-sectional, retrospective multicenter study, we analyzed IBM-FRS total score (TS) and its items in a cohort of 147 IBM patients, considering 4 functional domains (FD) (dysphagia, upper limb function, daily living and independence, lower limb function). We analyzed TS and FD values' correlations with demographic and clinical variables (onset, loss of walking ability, non-invasive ventilation, percutaneous gastrostomy-PEG) as well as between each FD and the remaining TS. Lower, hence worse, scores in the dysphagia domain (FD1) correlated with female gender (p < 0.01), dysphagia as presenting symptom (p < 0.01), and PEG use (p < 0.0001), but interestingly without correlation with time variables IBM-FRS total score or other domains. This may define a distinct phenotype with different onset and outcome. Worse scores in the upper and lower limb and daily living domains (FD2-FD4) were strongly associated with loss of ambulation, higher age at baseline, and longer disease duration (p < 0.001). We identified a cutoff value of 28/40, allowing to differentiate patients with less disease burden, potentially able to show better response in future clinical trials. Our study enriches the literature by correlating IBM-FRS total scores and its items with patient characteristics, offering important implications for clinical management, subgroup analysis, and future trials design.

Keywords: IBM; IBM-FRS; Inclusion body myositis; Myositis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: LM has received honoraria for speaking, advisory boards, and compensation for congress participations from Sanofi, Roche, Biogen, Amicus Therapeutics, Alexion, Argenx, UCB, Johnson & Johnson, and Lupin, outside the submitted work. CHUV received for MT honoraria for speaking, advisory boards, and compensation for congress participations from Sanofi, Roche, Biogen, Alexion, Argenx, UCB, Johnson & Johnson, Alnylam, AstraZeneca, and Takeda, outside the submitted work. ES has received honoraria for speaking, advisory boards, and compensation for congress participation from Roche, Biogen, Alexion, Argenx, and UCB, not related to the submitted work. MC has received honoraria for speaking, advisory boards, and compensation for congress participation from Roche and Biogen. EMC has received honoraria for speaking, advisory boards, and compensation for congress participation from Roche and Biogen, not related to the submitted work. Ethical approval: The study was conducted according to the Helsinki Declaration and its protocol was approved by the regional ethics committee “Lombardia 4” under the registered study number CET 17/24. Aggregated anonymized data were analyzed.

References

    1. Lilleker JB, Naddaf E, Saris CGJ, Schmidt J, de Visser M, Weihl CC, Alexanderson H, Alfano L, Allenbach Y, Badrising U, Benveniste O, Bhai S, De Bleecker J, Breeveld MC, Chinoy H, Diederichsen L, Dimachkie M, Greenberg S, Johari M, Lilleker J, Lindgren U, Lloyd T, Machado P, Mozaffar T, Mischke R, Needham M, Nishino I, Oldfors A, Saris C, Stenzel W, Tasca G, Weihl C (2024) 272nd ENMC international workshop: 10 Years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16–18 June 2023, Hoofddorp, The Netherlands. Neuromuscul Disord 37:36–51. https://doi.org/10.1016/j.nmd.2024.03.001 - DOI - PubMed
    1. Benveniste O, Stenzel W, Hilton-Jones D et al (2015) Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol 129:611–624. https://doi.org/10.1007/s00401-015-1384-5 - DOI - PubMed - PMC
    1. Kleefeld F, Uruha A, Schänzer A et al (2022) Morphologic and molecular patterns of polymyositis with mitochondrial pathology and inclusion body myositis. Neurology. https://doi.org/10.1212/WNL.0000000000201103 - DOI - PubMed
    1. Winkler M, Von Landenberg C, Kappes-Horn K et al (2021) Diagnosis and clinical development of sporadic inclusion body myositis and polymyositis with mitochondrial pathology: a single-center retrospective analysis. J Neuropathol Exp Neurol 80:1060–1067. https://doi.org/10.1093/jnen/nlab101 - DOI - PubMed
    1. Shelly S, Mielke MM, Mandrekar J, Milone M, Ernste FC, Naddaf E, Liewluck T (2021) Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology 96(21):e2653–e2661. https://doi.org/10.1212/WNL.0000000000012004 - DOI - PubMed - PMC

Publication types

LinkOut - more resources